Anne Cayre

<i>KRAS</i> Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

Astrid Lièvre, Jean‐Baptiste Bachet, Valérie Boige et al. · Journal of Clinical Oncology · 2008 · 1.4K citations · Full text

Analysis of <i>PTEN</i> , <i>BRAF</i> , and <i>EGFR</i> Status in Determining Benefit From Cetuximab Therapy in Wild-Type <i>KRAS</i> Metastatic Colon Cancer

Pierre Laurent‐Puig, Anne Cayre, Gilles Manceau et al. · Journal of Clinical Oncology · 2009 · 665 citations

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

Michèle Beau‐Faller, Nathalie Prim, Anne-Marie Ruppert et al. · Annals of Oncology · 2013 · 312 citations · Full text

Rare Egfr, Non-small-cell Lung Cancer, Medicine +8

Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact

Jean‐Marc Nabholtz, Catherine Abrial, Marie‐Ange Mouret‐Reynier et al. · Annals of Oncology · 2014 · 122 citations

Breast Oncology, Medicine, Treatment Impact +8

aHIF but not HIF-1α transcript is a poor prognostic marker in human breast cancer

Anne Cayre, Fabrice Rossignol, Eric Clottes et al. · Breast Cancer Research · 2003 · 91 citations · Full text